LivaNova Beats Q2 Estimates, Raises Full-Year Guidance on Strong Cardiopulmonary and Neuromodulation Growth
LIVN sits 82% above its 52-week low of $41.87.
Summary
LivaNova posted Q2 revenue of $390.6M (+10.8%), beating estimates, and raised full-year guidance. Net income surged to $108.6M, aided by a $95.4M tax benefit. The aura6000 sleep apnea device received FDA approval, and the company repaid its remaining term debt.
Key Events · Earnings and Guidance · LIVN
-
Q2 Revenue and EPS Beat
Revenue of $390.6M grew 10.8% reported, exceeding estimates. Diluted EPS of $1.93 compared to $0.50 in Q2 2025, driven by strong segment performance and a $95.4M discrete tax benefit.
-
Full-Year Guidance Raised
Management increased full-year 2026 revenue and EPS guidance, reflecting confidence in sustained growth across both Cardiopulmonary and Neuromodulation segments.
-
aura6000 FDA Approval and Milestone Payment
The FDA granted PMA for the aura6000 obstructive sleep apnea device in March 2026, triggering a $60.5M milestone payment to ImThera. The device addresses a large, underserved market.
-
Debt Repayment Strengthens Balance Sheet
The remaining $95.9M Term Facilities balance was repaid in January 2026, reducing total debt to $290.1M. Interest expense fell to $7.2M from $14.9M a year ago.
Analysis · LIVN · Industrial Applications And Services
LivaNova delivered a strong Q2 with revenue of $390.6 million, up 10.8% reported, beating consensus. Both segments grew double digits, driven by Essenz perfusion system sales and VNS Therapy volume. Management raised full-year revenue and EPS guidance, signaling confidence in sustained momentum. A $95.4 million discrete tax benefit from an Italian ruling on SNIA liability deductibility boosted net income to $108.6 million. The quarter also saw the FDA approval of the aura6000 OSA device, triggering a $60.5 million milestone payment, and the final $95.9 million repayment of term loans, strengthening the balance sheet. The only blemish was a higher 3T litigation provision, but the overall picture is one of accelerating operational performance and improving financial flexibility.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 36.1% of the 1051 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.56%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, LIVN was trading at $76.37 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $4.2B. The 52-week trading range was $41.87 to $85.76. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.